The statistically significant improvements seen in key HS symptoms during GLP-1 treatment for obesity suggest overlap in both mechanistic and immunologic effects.

New data show more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

The GLP-1/GIP receptor agonist also showed promise in an exploratory maintenance arm, producing rapid weight loss at an induction dose that was sustained after down-titration.

Your daily dose of the clinical news you may have missed.

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.

Family physician Sarah Sams, MD, shares practical strategies on vaccine updates, coadministration, and addressing hesitancy this respiratory season.

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.